Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q1 2022 · 10-Q
Revenue$720.00M$720.00M+7.4% vs Q1 2021 Net Income$173.80M$173.80M+14.9% vs Q1 2021 EPS Diluted$2.29$2.29+15.1% vs Q1 2021 Gross Profit$284,600,000+4.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flow$151,200,000+70.5% Free Cash Flowderived$85,400,000+151.2% Margins · derivedGross margin39.5%−1.0 pt vs Q1 2021
Operating margin26.3%+0.2 pt vs Q1 2021
Net margin24.1%+1.6 pt vs Q1 2021
ended Mar 31, 2022 · filed Apr 28, 2022 · 28 d after period end